National Bank of Canada FI increased its stake in Astrazeneca Plc (NYSE:AZN – Free Report) by 99.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,236,063 shares of the company’s stock after purchasing an additional 1,116,871 shares during the quarter. National Bank of Canada FI owned about 0.14% of Astrazeneca worth $392,429,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the stock. Bank of America Corp DE lifted its holdings in Astrazeneca by 4.7% in the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after purchasing an additional 1,461,786 shares during the period. Fisher Asset Management LLC lifted its holdings in Astrazeneca by 2.1% in the fourth quarter. Fisher Asset Management LLC now owns 21,601,433 shares of the company’s stock worth $3,791,051,000 after purchasing an additional 438,709 shares during the period. Franklin Resources Inc. lifted its holdings in Astrazeneca by 2.3% in the fourth quarter. Franklin Resources Inc. now owns 20,157,744 shares of the company’s stock worth $3,537,684,000 after purchasing an additional 445,014 shares during the period. Morgan Stanley lifted its holdings in Astrazeneca by 3.2% in the fourth quarter. Morgan Stanley now owns 13,878,726 shares of the company’s stock worth $2,435,716,000 after purchasing an additional 432,939 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Astrazeneca by 9.4% in the third quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock worth $521,517,000 after purchasing an additional 582,183 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.
Astrazeneca Price Performance
NYSE AZN opened at $178.79 on Wednesday. The stock’s 50-day moving average price is $188.26 and its two-hundred day moving average price is $186.16. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The company has a market cap of $277.29 billion, a PE ratio of 26.85, a PEG ratio of 1.54 and a beta of 0.25. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Finally, TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Astrazeneca has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.
Read Our Latest Report on Astrazeneca
About Astrazeneca
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
- Five stocks we like better than Astrazeneca
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
